PPA
DNLI icon

Parametric Portfolio Associates’s Denali Therapeutics DNLI Stock Holding History

Parametric Portfolio Associates’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$887K Sell
27,557
-4,887
-15% -$168K ﹤0.01% 2833
2021
Q4 		$1.45M Sell
32,444
-554
-2% -$26.2K ﹤0.01% 2626
2021
Q3 		$1.67M Sell
32,998
-31,211
-49% -$1.76M ﹤0.01% 2534
2021
Q2 		$5.04M Buy
64,209
+20,390
+47% +$1.26M ﹤0.01% 1849
2021
Q1 		$2.5M Sell
43,819
-2,596
-6% -$174K ﹤0.01% 2630
2020
Q4 		$3.89M Sell
46,415
-10,002
-18% -$605K ﹤0.01% 2236
2020
Q3 		$2.02M Buy
56,417
+40,027
+244% +$1.21M ﹤0.01% 2504
2020
Q2 		$396K Buy
16,390
+4,514
+38% +$106K ﹤0.01% 3367
2020
Q1 		$208K Sell
11,876
-46
-0.4% -$960 ﹤0.01% 3535
2019
Q4 		$208K Sell
11,922
-344
-3% -$5.73K ﹤0.01% 3730
2019
Q3 		$188K Buy
+12,266
New +$234K ﹤0.01% 3728

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Parametric Portfolio Associates's DNLI Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Denali Therapeutics (DNLI) stake by 15% in Q1 2022, selling an estimated $168K and leaving 27,557 shares worth $887K. The position accounts for ﹤0.01% of the portfolio, ranked #2833.

Parametric Portfolio Associates first reported a position in DNLI in Q3 2019 and has held it in 11 quarters since. The position peaked at $5.04M in Q2 2021. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

  • Parametric Portfolio Associates held 27,557 shares of Denali Therapeutics worth $887K as of Q1 2022.
  • Parametric Portfolio Associates sold 4,887 Denali Therapeutics shares in Q1 2022, an estimated $168K.
  • Denali Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2833 holding.
  • Parametric Portfolio Associates first reported a position in Denali Therapeutics in Q3 2019 and has held it in 11 quarters since.
  • Parametric Portfolio Associates's Denali Therapeutics position peaked at $5.04M in Q2 2021.
  • 190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.